🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are proud to announce that #4oncommunity is now online!!! 4oncommunity.com [email protected] @NicolaFuscoMD Matteo Fassan OncoAlert Christian Rolfo International Society of Liquid Biopsy Pasquale Pisapia Alessandro Russo Valerio Gristina Gil Morgan, MD pvukovic Kamran Mirza MD PhD - کامران مرزا Dr. Iván R. González

Every cancer patient deserves a complete diagnosis.

"Coke vs Pepsi"? Osi vs Lazer in MARIPOSA trial looks a lot alike. Matter of preference? Stephen V Liu, MD

Agree Stephen V Liu, MD I also prefer Coke (Coca-Cola)

So true Steve Lee Incredibly important issue for physicians and health care systems, but most of all for our patients who are losing this safety net. Unbelievable that this is happening in a democracy based on offering hope and opportunity for so many for long.

Lung-MAP 3.0’s easier genetic screening process means Lung-MAP will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org Foundation for the National Institutes of Health Friends of Cancer Research SWOG Cancer Research Network National Cancer Institute

How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, Clarissa Mathias moderates a discussion with Guilherme Harada and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. 🎧 Listen now: bit.ly/VTBport

Thanks for sharing Tom Newsom-Davis Agree, an astounding number of trials in this space. Let's hope that more than a few of them lead to meaningful benefits for our patients IASLC ASCO

🫁 How are IMFORTE and DeLLphi-304 changing the standard of care for SCLC? 🌟 In this insightful new interview, Stephen V Liu, MD unpacks the #ASCO25 data and what it means for the treatment landscape. ➡️ Watch now: buff.ly/Hh4YzLi #lcsm #SCLC #ASCO2025

Right fit for this position Stephen V Liu, MD People person, self-motivated, knows what is needed to reach goals. Congratulations! 👏👏👏

“What counts in life is not the mere fact that we have lived. It is what difference we have made to the lives of others that will determine the significance of the life we lead” - Nelson Mandela

🧬Longitudinal Monitoring of ctDNA for Whole-Course Management in NSCLC Patients LUNGCA prospective multicenter cohort study JNCI: Journal of the National Cancer Institute, 2025 🔍 Background Circulating tumor DNA (ctDNA) is a promising tool for detecting minimal residual

Sometimes you just have to take a deep breath and move on. Other times you need to ventilate. This is one of those times.

📢 Abstract Submission & Registration Are Now Open for #ISLB25! Join the international #liquidbiopsy community in Orlando, Florida, from November 1–3, 2025, for the 7th Annual Congress of Liquid Biopsy. Submit your research: 2025.islb.info/call-for-abstr… Register early to save:

That feeling when 7+ years of work lands on the front page of NEJM—and one of the people I respect most, Kohei shitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn Memorial Sloan Kettering Cancer Center

🔥Off the press: ASCO #LivingGuidelines for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 | 👉🏽 ascopubs.org/doi/10.1200/JC… ✅ Clear algorithm for first and second line options ✅ Review of recent data:

💊 How will the accelerated approval of sunvozertinib shape the treatment landscape for EGFR+ #NSCLC? 🌟 In this new interview, Stephen V Liu, MD, weighs in on the implications of the accelerated approval & what could be on the horizon. ➡️ Watch: buff.ly/LjnPRSp #lcsm

At NOSCM, Julia Rotow MD presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

our #lungcancer session at MECC New Orleans 2025 with David Gandara IASLC Karen Kelly Eric K. Singhi, MD Julia Rotow MD Paul Bunn Subramanian Fred R. Hirsch Edgardo S. Santos, M.D., FACP, FASCO Megan Daly Erminia Mazarelli #lcsm The Medical Educator Consortium

Diving beyond EGFR in NSCLC with an excellent session chaired by Erin Schenk, MD, PhD, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from Christine Garcia, MD, MPH David Gandara Mihaela Aldea Jorge Nieva Jonathan Riess, MD MS OncLive.com #BTGLung2025 #LCSM #Oncology